Valuation: TaiRx, Inc.

Market Cap 1.4B 43.29M 37.84M 34.96M 32.16M 60.62M 4.17B 62.11M 418M 164M 2.04B 163M 159M 7.03B P/E 2024
-20.5x
P/E 2025 -11x
Enterprise Value 1.07B 33.09M 28.92M 26.72M 24.58M 46.33M 3.19B 47.47M 320M 125M 1.56B 124M 122M 5.38B EV / Sales 2024
286x
EV / Sales 2025 75.1x
Free-Float
100%
Yield 2024 *
-
Yield 2025 -
1 week-4.21%
Current month-7.06%
1 month-11.35%
3 months-30.36%
6 months-41.86%
Current year-42.92%
1 week 12.2
Extreme 12.2
13.05
1 month 12.2
Extreme 12.2
14.5
Current year 12.2
Extreme 12.2
23.45
1 year 12.2
Extreme 12.2
31.8
3 years 12.2
Extreme 12.2
44
5 years 12.2
Extreme 12.2
89.5
10 years 12.2
Extreme 12.2
89.5
Manager TitleAgeSince
Investor Relations Contact - -
Chief Executive Officer - 2011-08-21
Director of Finance/CFO - 2015-10-04
Director TitleAgeSince
Chairman - 2011-08-21
Director/Board Member - 2013-12-17
Director/Board Member - 2011-08-21
Change 5-day change 1-year change 3-year change Capi.($)
0.00%-4.21%-45.89%-60.32% 43.25M
-1.29%-3.11%-0.35%+3.09% 49.18B
+3.90%-0.39%+386.06%+588.97% 39.58B
-1.70%+4.46%+5.93%+61.54% 34.69B
-2.01%-0.76%+28.41%-8.52% 34.42B
+0.06%+0.34%+2.38%+34.38% 27.11B
+0.46%-3.49% - - 16.21B
-0.04%-0.09%+72.42%+116.45% 15.36B
+1.12%+1.91%+14.54%+15.44% 14.05B
0.00%+1.36%+18.43%-31.23% 13.02B
Average +0.05%-0.32%+53.55%+79.98% 24.37B
Weighted average by Cap. -0.05%-0.18%+79.42%+122.36%

Financials

2024 2025
Net sales 8.22M 254K 222K 205K 189K 356K 24.45M 364K 2.45M 963K 11.96M 954K 933K 41.27M 27.88M 861K 753K 695K 640K 1.21M 82.9M 1.24M 8.32M 3.27M 40.54M 3.23M 3.16M 140M
Net income -139M -4.29M -3.75M -3.46M -3.19M -6M -413M -6.15M -41.43M -16.27M -202M -16.1M -15.75M -697M -221M -6.83M -5.97M -5.52M -5.07M -9.56M -658M -9.8M -65.99M -25.91M -322M -25.65M -25.09M -1.11B
Net Debt -505M -15.6M -13.63M -12.6M -11.59M -21.84M -1.5B -22.37M -151M -59.15M -734M -58.56M -57.28M -2.53B -330M -10.21M -8.92M -8.24M -7.58M -14.29M -983M -14.64M -98.6M -38.71M -481M -38.33M -37.48M -1.66B
Logo TaiRx, Inc.
TaiRx Inc is a Taiwan-based company mainly engaged in the development and research of new drugs. The Company primarily focus on the research and development of cancer treatment drugs and sepsis adjuvant therapy drugs. The Company's main products include CVM-1118, Rexis, Zelnite, TRX-NOC, TRX-920, TRX-711, TRX-105 and others. CVM-1118 and Rexis are in clinical trials, and Zelnite drugs are sold to domestic medical institutions at all levels through distributors.
Employees
-
Date Price Change Volume
26-07-17 NT$12.50 0.00% 57,119
26-07-16 NT$12.50 -0.40% 31,197
26-07-15 NT$12.55 -0.40% 50,854
26-07-14 NT$12.60 -2.70% 80,448
  1. Stock Market
  2. Stocks
  3. 6580 Stock